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1848theme that can be derived from our study and the
study by Bikdeli et al. (2) is that the burden of infec-
tive endocarditis hospitalization rates in the United
States is high and rising, which ultimately confers
to higher health care expenditure and morbidity.
Hence, a multispecialty collaborative effort is needed
to understand the factors responsible and identify the
strategies to halt this rising trend. We believe that
the ongoing monitoring of the impact of the prophy-
laxis guidelines and appropriate updates on the basis
of such data is an essential step in this regard.Sadip Pant, MD
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Risk During the Statin Era?The Schwartz et al. (1) paper reported that among
patients with acute coronary syndrome treated
effectively with statins, fasting triglycerides (Tg)
predict long-term and short-term cardiovascular risk.
Triglyceride-rich lipoproteins may be an important
additional target for therapy (1).
Lowering low-density lipoprotein cholesterol
(LDL-C) is the primary target in the management of
dyslipidemia in patients at high risk of cardiovas-
cular disease. However, patients who have achieved
LDL-C levels below the currently recommended
targets may still experience cardiovascular events.
This may result, in part, from elevated Tg levels (2).
Atherogenic dyslipidemia, characterized by high Tg,low levels of high-density lipoprotein cholesterol
(HDL-C), and small, dense LDL particles, is a typical
phenotype of dyslipidemia in subjects with insulin
resistance and metabolic syndrome. On the other
hand, raised Tg concentrations are strongly associ-
ated with low concentrations of HDL-C, and the past
15 years have been dominated by HDL research, with
less focus on Tg. However, the understanding from
genetic studies and randomized trials that low HDL-C
might not be a cause of cardiovascular disease as
originally thought has generated renewed interest in
raised Tg (3). Indeed, a study investigated the causal
role of HDL-C and Tg using multiple instrumental
variables for Mendelian randomization and reported
that the genetic ﬁndings supported a causal effect of
Tg on coronary heart disease risk (4).
It is obvious that statins are the ﬁrst-line drug for
the treatment of dyslipidemia. However, a strategy
to reduce high Tg and modify the small, dense
LDL particles is required. In this regard, statin-based
combined with ﬁbrates, peroxisome proliferator-
activated receptor agonists may be recommended in
addition to therapeutic lifestyle changes if patients
still experience cardiovascular events. The cost
effectiveness of these combinations should also be
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